Announced Date: 2023-12-11 (December 11, 2023)
Asset Name: BL-B01D1
Licensor: SystImmune Inc., (a member of Sichuan Biokin Pharmaceutical Co., Ltd group., China)
Licensee (Buyer): Bristol Myers Squibb（BMS）
Asset Modality: BsADC (bispecific antibody-drug conjugate), topoisomerase inhibitor-based
Asset Target: EGFRxHER3 (epidermal growth factor receptor, human epidermal growth factor receptor 3)
Potential Indication: lung and breast cancer, may expand into additional tumor types
Current Stage: global multi-center Phase 1 study
Scope of Authority:
SystImmune and Bristol Myers Squibb to co-develop and co-commercialize BL-B01D1 in the United States;
SystImmune to retain exclusive rights in Mainland China and Bristol Myers Squibb to gain an exclusive license in the rest of the world.
Deal Detail:
Upfront payment of $800 million,
Near-term payments up to $500 million,
Development, regulatory and sales performance milestones payments up to $ $7.1 billion,
Total up to $8.4 billion.
Bristol Myers Squibb will receive a royalty on net sales in Mainland China,
SystImmune will receive a tiered royalty on net sales Outside the United States and Mainland China.
Link:
